Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
6(66.7%)
Phase 2
3(33.3%)
9Total
Phase 1(6)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT07223216Phase 1Active Not Recruiting

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

Role: lead

NCT07502508Phase 2Recruiting

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Role: lead

NCT07502495Phase 2Recruiting

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

Role: lead

NCT05918692Phase 1Active Not Recruiting

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

Role: lead

NCT07254286Phase 1Completed

Food Effect Study in Healthy Volunteers

Role: lead

NCT05731544Phase 1Completed

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

Role: lead

NCT06152042Phase 2Terminated

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

Role: lead

NCT05153330Phase 1Terminated

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Role: lead

NCT05631574Phase 1Terminated

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Role: lead

All 9 trials loaded